HUMULIN 70/30

Combination product

Combination of Insulin NPH and Insulin regular, premixed 70/30 in one pen.

Each component keeps its own pharmacology page; the combination itself adds no new mechanism.

Components (2)

FDA dosing	Population	Start	Target	Max
Diabetes mellitus (glycemic control)	Adults	Individualized	Individualized	Individualized

Renal Not studied; patients at increased hypoglycemia risk may require more frequent dose adjustment and glucose monitoring

Hepatic Not studied; patients at increased hypoglycemia risk may require more frequent dose adjustment and glucose monitoring

Administer 30-45 minutes before a meal

Inject subcutaneously approximately 30-45 minutes before a meal (abdominal wall, thigh, upper arm, or buttocks); rotate sites
Do not administer intravenously or in an insulin infusion pump
Do not mix with any other insulins or diluents
Fixed 70% NPH / 30% regular ratio — independent basal/prandial adjustment not possible

Available strengths

Pregnancy Published data over decades have not established an association with adverse outcomes

Lactation Exogenous human insulin transferred into human milk; no adverse reactions reported in breastfed infants

HUMULIN 70/30

What pharmacies pay · NADAC 9/30/26 · OTC

Strength		#/mo	generic $/unit	brand $/unit	CostPlus
1 [iu]/ml	inj	per unit		—	not offered
100 [iu]/ml	inj	per unit	—	$4.63/mL	not offered
500 [iu]/ml	inj	per unit	—	$91.61/mL	not offered

Therapeutic safety burden3 / 4

Overdose danger4 / 4

Weight-gain liability3 / 4

Sedation liability0 / 4

QT / Torsades0 / 4

Direct muscarinic antagonism0 / 4

Embryofetal risk0 / 4

Defining liabilityMeal-dependent hypoglycemia, dosing errors and weight gain

Part D rank #273.